Kite, Genentech to study combo for NHL

Kite Pharma Inc. (NASDAQ:KITE) said it will partner with the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to conduct a clinical trial of Kite's chimeric antigen receptor (CAR) T cell therapy KTE-C19 in combination with Genentech's anti- PD-L1 mAb atezolizumab ( MPDL3280A). Kite said the partners expect to begin the Phase Ib/II trial this year to treat refractory non-Hodgkin's lymphoma.

Kite spokesperson Justin Jackson said the partners will co-fund the study. ...